Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended …

…, LH Yoke, AB Braimah, JJ Orozco… - Clinical Infectious …, 2023 - academic.oup.com
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after …

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model

…, SHL Frost, AK Gopal, JJ Orozco… - Blood, The Journal …, 2015 - ashpublications.org
α-Emitting radionuclides deposit a large amount of energy within a few cell diameters and
may be particularly effective for radioimmunotherapy targeting minimal residual disease (MRD)…

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

…, AK Gopal, TA Gooley, JJ Orozco… - Blood, The Journal …, 2018 - ashpublications.org
Pretargeted radioimmunotherapy (PRIT) has demonstrated remarkable efficacy targeting
tumor antigens, but immunogenicity and endogenous biotin blocking may limit clinical …

Quantitative single‐particle digital autoradiography with α‐particle emitters for targeted radionuclide therapy using the iQID camera

…, DK Hamlin, DS Wilbur, DR Fisher, JJ Orozco… - Medical …, 2015 - Wiley Online Library
Purpose: Alpha‐emitting radionuclides exhibit a potential advantage for cancer treatments
because they release large amounts of ionizing energy over a few cell diameters (50–80 μm), …

Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model

JJ Orozco, T Bäck, A Kenoyer, ER Balkin… - Blood, The Journal …, 2013 - ashpublications.org
Despite aggressive chemotherapy combined with hematopoietic stem cell transplantation (HSCT),
many patients with acute myeloid leukemia (AML) relapse. Radioimmunotherapy (RIT…

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

S O'Steen, ML Comstock, JJ Orozco… - Blood, The Journal …, 2019 - ashpublications.org
Minimal residual disease (MRD) has become an increasingly prevalent and important entity
in multiple myeloma (MM). Despite deepening responses to frontline therapy, roughly 75% …

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies

…, AL Kenoyer, SL Frayo, AK Gopal, JJ Orozco… - Cancer research, 2014 - AACR
The vast majority of patients with plasma cell neoplasms die of progressive disease despite
high response rates to novel agents. Malignant plasma cells are very radiosensitive, but the …

[HTML][HTML] cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced …

…, RL Manger, M Nartea, AL Kenoyer, JJ Orozco… - PLoS …, 2018 - journals.plos.org
The objective of this study was to translate reaction conditions and quality control methods
used for production of an astatine-211( 211 At)-labeled anti-CD45 monoclonal antibody (MAb…

[HTML][HTML] Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in …

…, TR Chauncey, SD Smith, M Philip, JJ Orozco… - Biology of Blood and …, 2016 - Elsevier
Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL)
in remission after induction chemotherapy, with the best results for patients in complete …

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft …

…, S Frayo, A Axtman, N Orgun, J Orozco… - Blood, The Journal …, 2011 - ashpublications.org
Pretargeted radioimmunotherapy (PRIT) using an anti-CD45 antibody (Ab)–streptavidin (SA)
conjugate and DOTA-biotin labeled with β-emitting radionuclides has been explored as a …